Vanda Pharmaceuticals (VNDA) Operating Income (2016 - 2025)
Historic Operating Income for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to -$40.4 million.
- Vanda Pharmaceuticals' Operating Income fell 29257.71% to -$40.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$151.2 million, marking a year-over-year decrease of 27178.55%. This contributed to the annual value of -$151.2 million for FY2025, which is 27178.55% down from last year.
- According to the latest figures from Q4 2025, Vanda Pharmaceuticals' Operating Income is -$40.4 million, which was down 29257.71% from -$31.3 million recorded in Q3 2025.
- Vanda Pharmaceuticals' Operating Income's 5-year high stood at $12.4 million during Q2 2021, with a 5-year trough of -$41.0 million in Q1 2025.
- For the 5-year period, Vanda Pharmaceuticals' Operating Income averaged around -$7.9 million, with its median value being -$6.5 million (2023).
- As far as peak fluctuations go, Vanda Pharmaceuticals' Operating Income soared by 837280.0% in 2021, and later crashed by 56082.83% in 2024.
- Vanda Pharmaceuticals' Operating Income (Quarter) stood at $8.6 million in 2021, then fell by 23.24% to $6.6 million in 2022, then tumbled by 207.01% to -$7.1 million in 2023, then tumbled by 44.9% to -$10.3 million in 2024, then crashed by 292.58% to -$40.4 million in 2025.
- Its Operating Income stands at -$40.4 million for Q4 2025, versus -$31.3 million for Q3 2025 and -$38.5 million for Q2 2025.